To determine the incidence and clinical manifestations of human breast milk (HMB)-associated acquired cytomegalovirus (CMV) infection in small premature infants.
INTRODUCTION
Cytomegalovirus (CMV) infection in small premature babies during the first weeks of life, in contrast to acquired CMV in term infants 1, 2 can cause severe and possibly life-threatening disease 3 and may be a cofactor in the development of long-term neurological sequelae. 3 In the past, such CMV infections have been attributed mainly to transfusion of blood products from seropositive donors. However, despite the use of filtered blood products or blood products from seronegative donors, premature infants continue to acquire the infection. [1] [2] [3] [4] [5] In mothers with apparent latent CMV infection, the virus reactivates in their milk during the postpartum period and is transmitted to their breast-fed infants with the peak CMV load occurring 4-6 weeks after birth. [6] [7] [8] Hamprecht et al. 6 recently assessed the transmission rate and clinical significance of CMV transmission in breast milk-fed premature babies who were born at 32 weeks of gestation or less and/or weighed 1500 g or less at birth. In 73 (96%) of 76 seropositive mothers, CMV-DNA was detected in breast milk at some point during lactation, and 33 (38%) of their 87 human breast milk (HBM)-fed babies premature infants acquired the infection. However, none of 80 HBM-fed babies born to 69 seronegative mothers became infected. A total of 16 (48%) of the infected babies had at least one clinical sign of infection, most commonly, absolute neutropenia (42%). Four (25%) babies who acquired CMV during the first 8 weeks of life suffered from severe symptomatic disease.
Given the fact that breast milk is recommended as the most appropriate diet in all infants regardless of gestational age at delivery 1,9-11 this potentially poses a therapeutic dilemma for those caring for premature infants. Additionally concern arises from the reports of increased long-term morbidity (mainly hearing loss and/ or developmental retardation) in premature babies who acquired CMV infection at age <8 weeks. [3] [4] [5] Several studies, however, in which HBM that had been preserved in À201C before feeding premature babies was used, have noted no incidence of CMV infection. 8, 12 Thus, our study was designed to prospectively assess the rate and clinical manifestation of HBM-associated CMV infection in the immature and very low birth weight (VLBW) (birth weight <1500 g) premature population in the first 8 weeks of life.
PATIENTS AND METHODS
The study was conducted between 1 June 1999 and 31 May 2002 in two neonatal intensive care units in Israel F Ha'Emek Medical center, Afula and Shaare Zedek Medical Center, Jerusalem. Human investigation review boards in both hospitals approved the study and informed consent was obtained from mothers of all babies before inclusion. The study population included all premature neonates born during the study period with gestational age r32 weeks and/or weight r1500 g at birth.
STUDY DESIGN
Blood samples were obtained from all mothers at enrolment and tested for IgM and IgG antibodies to CMV (CMV IgM/IgG EIA recomb. Roche Diagnostics GmbH, D-68298, Mannheim). Hamprecht et al. 6 have noted the rate of CMV reactivation to be nearly equal to the rate of seropositivity and that CMV appeared in the urine in all infected babies. Yasuda et al. 8 recently confirmed these results. Therefore, we considered all breast-feeding seropositive women to be potentially infectious to their babies and did not assess CMV in breast milk.
Breast milk was refrigerated at 2-81C and fed to the babies within 24 hours after obtaining from mothers. HBM-fed babies received 8 to 12 feedings per day throughout the study period (8 weeks). Infants were followed for 8 weeks or until they reached the weight of 2000 g and discharged from the NICU.
Urine specimens were collected into a sterile urine-bag attached to the perineum after thorough cleaning. All the urine specimens were processed in the Infectious Diseases Molecular Diagnostic Laboratory at Shaare Zedek Medical Center. The specimens from Center 1 were stored at 41C, and transported on ice within 1 week to the laboratory. All the urine specimens were processed and used for CMV PCR reaction as recently described by our group in details. 13 In that study we have shown the high sensitivity and specificity of the PCR assay. In a prestudy sensitivity assay, the PCR reaction was positive in 99 of 100 urine specimens (99% sensitivity) spiked with as low as 20 to 30 viral copies/reaction. Specimens found to be positive by PCR were validated by conventional tube culture method. Hence, we consider the urine PCR assay as reliable as the conventional viral culture. The convenience of performing this assay on a large number of specimens makes it very suitable for screening purposes.
Horizontal CMV transmission was prevented by implementing contact isolation guidelines and the use of leukocyte filter (4c2223, Teva Medical) when infusing blood-products. All infants were followed daily for clinical signs suggestive of CMV infection such as clinical deterioration, hepatomegaly, jaundice, hepatitis, anemia, leucopenia, and thrombocytopenia.
The included neonates were divided into two groups: Group 1 included babies who had been fed HBM by seropositive mothers. Group 2 included babies who had been fed HBM by seronegative mothers and babies who had been fed formula only throughout the study period by both seropositive and seronegative mothers. Data were obtained for each enrolled subject, and included gestational age, birth weight, route of delivery and number of blood products received. Clinical assessment of each neonate was performed daily. If acute CMV disease was suspected or if the infant began to shed CMV in the urine, blood was drawn for liver function tests and complete blood count. Clinical course of the infection was monitored. HBM-associated CMV infection was defined as the appearance of CMV-DNA in the urine of previously uninfected HBM-fed baby of a CMV seropositive mother.
RESULTS
In total, 96 premature babies and their 77 mothers were included in the study. Of the 77, 72 mothers (92%) tested seropositive to CMV. In all, 26 neonates (26.3%) were delivered vaginally and 70 (73.7%) by cesarean section. Mean gestational age and weight at birth were 29.2±2.1 weeks (range 27 to 35 weeks), and 1242±230 g, respectively. A total of 57 (60%) neonates were born before or at 30 weeks of gestation. Overall, 18 babies weighed between 500 and 999 g at birth; 65 weighed between 1000 and 1500 g and 13 weighed more than 1500 g and were included in the study because they were born prior to 32 weeks gestation.
Totally, 70 neonates qualified for Group 1 and 26 for Group 2. No differences were found between the groups in regard to gestational age at delivery, birth weight, and route of delivery (Table 1) , as well as number of blood products received.
Four of the 70 HBM-fed neonates of CMV seropositive mothers became infected (5.7%, 95% CI 0 to 11%), as compared to none from Group 2. In all infected babies, CMV appeared in the urine at 3 to 7 weeks of age. One infected neonate had severe disease with respiratory deterioration, hemodynamic instability hepatosplenomegaly and elevated liver enzymes that coincided with appearance of CMV in the urine. Bacterial infection was ruled out by negative cultures. Two other infected infants had mild disease that presented as laboratory changes without apparent clinical disease, and the fourth had a completely asymptomatic infection ( Table 2 ). All of the infants recovered from acute disease, and all have had normal hearing, and development at routine 24-month follow-up.
DISCUSSION
In our study in which fresh unfrozen breast milk was used for feeding premature babies, the rate of HBM-associated CMV transmission to such babies in the first 8 weeks of life was 5.7% (4/70). Of importance is that the infection was transient with no sequela at 2-year follow-up. Since nearly all premature babies in Israel are HBM fed, and since the seroprevalence of CMV among fertile women in Israel is >85%, 14 it was difficult to recruit enough infants into Group 2. However, Hamprecht et al. 6 have documented no CMV infection in 80 premature babies of seronegative mothers who were fed by HBM that had not been frozen prior to feeding.
We note that there are other potential sources of perinatal and postnatal neonatal CMV infection, such as maternal saliva, urine, and vaginal secretions. However, it has been shown that these sources have negligible influence on CMV transmission to infants. 7, 8, 15 As shown by Hamprecht et al., none of 80 babies who were not exposed to CMV-positive HBM became infected. Additionally, most of the babies were born by cesarean section, and therefore were probably not exposed to cervical secretions. Only 12 (13%) HBM-fed preterm babies of seropositive mothers were delivered vaginally. In none of these babies was CMV cultured or CMV-DNA detected by PCR in throat and ear swabs taken immediately after delivery as a surrogate for cervical colonization (including 5 who later contracted the infection). 6 Further, Pugni et al. 16 have recently found that in only one of 48 CMV seropositive breast-feeding mothers was CMV cultured from vaginal secretions after birth. Consequently, in populations with a high rate of CMV seropositivity, HBM is most probably the major route of CMV acquisition by premature babies.
Literature analysis of CMV transmission rate in the first 8 weeks of life, which was available on 205 premature HBM-fed babies (including the current study), noted a rate of 12% with a range of 5 to 24%. 8, 12, 15, 16 Published data regarding HBM-associated CMV symptomatic infection in the same time period is available on 266 infants (including our study), and are summarized in Table 3 . *Two asymptomatic babies at birth were found to suffer from sensorineural hearing loss on follow-up.
The different results among these studies could be attributed to several factors. First, we have assessed only urine CMV as a measure of CMV infection while other studies have also assessed the virus in infant's blood [6] [7] [8] 16 and/or presence of CMV antibodies. 6 Following infection, the virus is first found in blood leukocyte and plasma, then seroconversion occurs with positive CMV IgM. Virus detection in urine is always the last step in the transmission cascade, often lagging up to 2 weeks behind the virus detection in the blood. 6, 7 It is therefore possible that we missed cases of asymptomatic CMV infection that would have been found positive had we tested plasma or serum. Secondly, in Yasuda et al. 8 and Sharland and Khare 12 studies, the breast milk was stored at À201C while in other studies it was stored in 41C for no more than 24 hours until feeding. No incidence of HBM-associated CMV infection was demonstrated in these two studies. An additional possible cause of the different attack rate is variations in birth weight and gestational age range among studies.
As shown in Table 3 , in only 13 of the 22 infected infants (defined as positive urine) were there symptoms and/or signs of infection. Six of these 13 babies suffered from a sepsis-like syndrome. In the other seven, laboratory data suggested an ongoing infective process. Out of the total 13 infants, 10 had neutropenia (1500/mm 3 ), but none had secondary opportunistic infections. In addition, five had evidence of mild hepatitis, and five had mild thrombocytopenia (<150,000). All laboratory abnormalities returned to normal prior to discharge.
Several factors may contribute to the relatively low rate of severe HBM-associated CMV infection found in our study. Data in the literature suggest that maternal antibodies transferred in utero have some protective effect. Yeager et al. 3 noted that fatal or serious symptoms developed in 50% of infected infants of seronegative mothers but in none of infected infants of seropositive mothers. The rate of congenital CMV infection and disease following reactivation of the virus during pregnancy is much lower than that of infection following maternal primary CMV infection. Also, the disease and late sequela of congenital CMV disease are less severe in infected babies following reactivation than primary infection during pregnancy. 1, 17 Seropositive renal transplant patients have lower rate of CMV disease following transplantation of kidney from seropositive donor. Moreover, therapy with hyperimmune anti-CMV gamma globulin is given to such seronegative patients after transplantation in order to prevent CMV infection and disease. 18 The nutritional importance of feeding premature babies with human milk is well established, and avoiding maternal milk may possibly raise overall morbidity and mortality by conditions such as sepsis and NEC. 1, 5, 19 If feeding with breast milk is desired, then preventing and/or minimizing transmission of CMV in the first 8 weeks of life by providing CMV-free milk should be the goal. This approach should be based on the principle of destruction or inactivation of CMV in HBM while preserving its nutritional and immunological properties. Freezing, pasteurization, and rapid heating of breast milk are some of the methods described for this purpose, but all have limitations. 1,7,11,12,20 -22 Freezing of the milk preserves the nutritional constituents, but is not completely effective in eliminating its infectivity. Jim et al. 21 have documented HMBassociated CMV transmission to premature babies although the breast milk was kept frozen at À181C before use. Moreover, as recently noted by Hamprecht et al., freezing breast milk at À201C preserved the biochemical and immunologic quality of the milk; however, late viral RNA and viral infectivity was also preserved (compared with viral DNA, CMV-RNA more directly reflects infectious CMV in human milk samples). 22 Pasteurization is highly effective in viral inactivating, but may damage lymphocytes and immunoglobulins in the milk. Short treatment of the milk at high temperature (721C for 5 seconds) is very effective for inactivating the CMV without deleterious effect on nutritional properties; however, this technique has not been thoroughly studied in clinical practice and is not commercially available. 1, 7, 22 Thus, until further data are available we believe that the policy should be to encourage breast-feeding of low birth weight infant with mother's-own fresh breast milk. As VLBW premature infants receiving human milk from seropositive mothers are at the highest risk for developing CMV infection, a high index of suspicion is required, including documentation of maternal CMV sero status and baseline neonatal screening for CMV infection. Appropriate subsequent studies to rule out acquired CMV infection should then be performed when such infants have either clinical or laboratory evidence of an otherwise unexplained deterioration. Although not completely effective, feeding of extremely immature infants by frozen human milk may be considered.
